Stockscreener 앱 받기
6.04
1.79%
-0.11
시간 외 거래:
6.12
0.08
+1.32%
전일 마감가:
$6.15
열려 있는:
$6.2
하루 거래량:
9,422
Relative Volume:
0.19
시가총액:
$67.54M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-11.57%
1개월 성능:
-13.84%
6개월 성능:
-24.12%
1년 성능:
+0.00%
1일 변동 폭
$6.04
$6.2999
1주일 범위
$6.04
$6.99
52주 변동 폭
$5.70
$17.96
Imagenebio Inc Stock (IMA) Company Profile
명칭
Imagenebio Inc
전화
857-343-8292
주소
12526 HIGH BLUFF DRIVE, SAN DIEGO
Compare IMA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMA
Imagenebio Inc
|
6.04 | 68.77M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Imagenebio Inc Stock (IMA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-25 | 재개 | Wedbush | Underperform |
| 2025-10-24 | 개시 | Leerink Partners | Outperform |
Imagenebio Inc 주식(IMA)의 최신 뉴스
ImageneBio Inc expected to post a loss of $1.45 a shareEarnings Preview - TradingView
IMA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
IMA,CVRX Dividends - Finviz
ImageneBio to Participate in Leerink Global Healthcare Conference - Eagle-Tribune
BML Capital Management LLC Makes New Investment in ImageneBio, Inc. $IMA - Defense World
ImageneBio (NASDAQ:IMA) Shares Up 2.4% – Still a Buy? - Defense World
ImageneBio announces immediate resignation of board director - TipRanks
ImageneBio (NASDAQ: IMA) prospectus supplement updates resale of 2.5M shares - Stock Titan
ImageneBio, Inc. Announces Resignation of Steven Hui Wang as Member of the Board of Directors, Effective on February 12, 2026 - marketscreener.com
ImageneBio (IMA) director Steven Hui Wang steps down from board - Stock Titan
ImageneBio appoints Dr. Porter-Brown as Chief Medical Officer By Investing.com - Investing.com Nigeria
ImageneBio appoints Dr. Porter-Brown as Chief Medical Officer - Investing.com South Africa
ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer - marketscreener.com
New ImageneBio CMO to lead late-stage eczema trial using OX40 drug - Stock Titan
ImageneBio Debuts on Nasdaq Following Merger Completion - AD HOC NEWS
ImageneBio (NASDAQ:IMA) Trading Up 0.5%Should You Buy? - MarketBeat
ImageneBio, Inc. (NASDAQ:IMA) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Joseph Slattery Spends US$96k On ImageneBio Stock - simplywall.st
ImageneBio Insider Confidence Rewarded, Stock Hits US$76m Market Cap - Yahoo Finance
Top ImageneBio Insider Makes Bold New Move on Company Stock - TipRanks
Joseph Slattery Buys 16,000 Shares of ImageneBio (NASDAQ:IMA) Stock - MarketBeat
ImageneBio chief medical officer resigns, transition planned - MSN
ImageneBio Chief Medical Officer Resigns, Transition Planned - TipRanks
ImageneBio, Inc. Announces Resignation of Yufang Lu as Chief Medical Officer, effective December 31, 2025 - marketscreener.com
ImageneBio assumed at Underperform from Neutral at Wedbush - MSN
ImageneBio, Inc. (NASDAQ:IMA) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
ImageneBio, Inc. (NASDAQ:IMA) Given Consensus Rating of “Hold” by Brokerages - Defense World
ImageneBio Extends Agreement with Miragene Inc. - MSN
ImageneBio (IMA) price target decreased by 94.20% to 16.32 - MSN
ImageneBio (IMA) Stock Analysis Report | Financials & Insights - Benzinga
ImageneBio, Inc. (IMA) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
ImageneBio, Inc. (IMA) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Wedbush Comments on ImageneBio's Q4 Earnings (NASDAQ:IMA) - MarketBeat
ImageneBio (NASDAQ:IMA) Lowered to “Underperform” Rating by Wedbush - Defense World
ImageneBio (NASDAQ:IMA) Rating Lowered to Underperform at Wedbush - Defense World
IMA interactive stock chart | ImageneBio, Inc. stock - Yahoo Finance Australia
Price performance - Yahoo Finance Australia
ImageneBio (NASDAQ:IMA) Downgraded to Underperform Rating by Wedbush - Defense World
ImageneBio (NASDAQ:IMA) Stock Rating Lowered by Wedbush - Defense World
Sell Recommendation for ImageneBio Due to Strategic Risks and Financial Challenges - TipRanks
Wedbush assumes coverage of ImageneBio stock with Underperform rating By Investing.com - Investing.com South Africa
ImageneBio (IMA) Receives Underperform Rating from Wedbush | IMA Stock News - GuruFocus
Wedbush assumes coverage of ImageneBio stock with Underperform rating - Investing.com India
Wedbush Assumes ImageneBio at Underperform With $2 Price Target vs. Prior Coverage at Underperform, $23 Price Target - marketscreener.com
ImageneBio reports Q3 EPS ($2.91) vs. ($2.58) last year - MSN
ImageneBio Highlights IMG-007 in Corporate Update - TipRanks
ImageneBio, Inc Updates Corporate Presentation for Q4 2025 - TradingView
FY2025 EPS Estimates for ImageneBio Cut by Leerink Partnrs - Defense World
William Blair Estimates ImageneBio FY2025 Earnings - Defense World
Here's Why We're Watching ImageneBio's (NASDAQ:IMA) Cash Burn Situation - Yahoo Finance
ImageneBio (NASDAQ:IMA) Downgraded by Wall Street Zen to “Strong Sell” - Defense World
Imagenebio Inc (IMA) 재무 분석
Imagenebio Inc (IMA)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
3.69%
0.68%
자본화:
|
볼륨(24시간):